SignatureFD’s Lineage Cell Therapeutics LCTX Stock Holding History

SignatureFD’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-400	Closed	–	–	2632
2020 Q3	$0	Hold	400	–	–	﹤0.01%	2687
2020 Q2	$0	Buy	+400	New	+$352	﹤0.01%	2588

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SignatureFD's LCTX Position: Q4 2020 in Review

SignatureFD sold out of Lineage Cell Therapeutics (LCTX) in Q4 2020, closing a stake of 400 shares.

SignatureFD first reported a position in LCTX in Q2 2020 and held it in 2 quarters. The position peaked at $0 in Q3 2020. 89 funds tracked by Wall St. Rank hold LCTX as of Q4 2020.

SignatureFD reported no remaining Lineage Cell Therapeutics position as of Q4 2020 after selling out during the quarter.
SignatureFD sold 400 Lineage Cell Therapeutics shares in Q4 2020.
SignatureFD first reported a position in Lineage Cell Therapeutics in Q2 2020 and held it in 2 quarters.
SignatureFD's Lineage Cell Therapeutics position peaked at $0 in Q3 2020.
89 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2020.

Based on SignatureFD's 13F filing for Q4 2020, filed 11 Feb 2021.